EN DE
Watch Enzymatica publ AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Enzymatica publ AB (ENZY) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Enzymatica publ AB stock SEK 1.69, price SEK 2.43, that is 30.5% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0003943620

EP Enzymatica publ AB logo Thin data Nov 10, 2026

Enzymatica publ AB

ENZY · ST
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Quality 47/100
Fair value kr 1.69 · Overvalued
Weak Growth (revenue 5y −13.5 %/yr in SEK)
Loss-making · -80.5% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Enzymatica publ AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 11.44 kr 1.36 Fair Value kr 1.69 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 1.36 – kr 11.44 · fair‑value band kr 1.27 – kr 2.12 · the kr 2.43 price screens above the kr 1.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Enzymatica publ in your weekly email

Every Wednesday you see whether Enzymatica publ is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms.

Show moreShow less

It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Stock analysis

Enzymatica publ AB (ENZY) currently trades at kr 2.43, while our estimate is kr 1.69, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 1.27 (bear) to kr 2.12 (bull), the price of kr 2.43 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Enzymatica publ AB reported revenue of 53.9M SEK in FY2025 versus 57.2M SEK in FY2021, a compound −1.5%/yr. Reported net income was −51.9M SEK in FY2025.

Key figures

Market cap 590M SEK (≈ $59.8M) Micro · P/S ratio 12.2 · EPS (TTM) kr −0.1800 · Net margin −80.5% · Return on equity −36.1% · Return on assets (EBIT) −33.9% (5-year average) · Operating margin −26.8% · Revenue (TTM) 51.5M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −30%, ENZY screens richer than that median.

Fair Value

Bear kr 1.27 Fair Value kr 1.69 Bull kr 2.12
Price kr 2.43 · Downside -30.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+18.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.5%
Start year 2020 (pandemic). Over 10 years: +6.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.8% (2020) → −96.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ENZY screens overvalued: fair value 30% below the price. Compare with Merck KGaA →

Compare Enzymatica publ AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −30.5% · Below median
Profitability
Return on assets −36.6% · Bottom 25%
Net margin (12 months) −80.5% · Bottom 25%
Operating margin (12 months) −26.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −2.9% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.75× · Priciest 25%
P/S (12 months) 11.46× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs ENZY
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs ENZY
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs ENZY
Haleon plc HLN $9.06 $8.62 −5% vs ENZY
Merck KGaA MRK €149.35 €109.18 −27% vs ENZY
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs ENZY
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs ENZY
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs ENZY
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs ENZY
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs ENZY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Enzymatica publ AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Enzymatica publ AB Fair Value". https://www.fairvalue-calculator.com/stock/ENZY

Frequently asked questions

Is Enzymatica publ AB (ENZY) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 1.69 versus a price of kr 2.43, about 30% lower (overvalued).
What is the fair value of ENZY?
Our estimate for Enzymatica publ AB is kr 1.69 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 2.43.
What is the quality score of ENZY?
Enzymatica publ AB has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enzymatica publ AB (ENZY)?
Our calculated price target is the estimate of kr 1.69 (as of Nov 10, 2026). Cautious scenario kr 1.27, optimistic scenario kr 2.12. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Enzymatica publ AB stock forecast for 2026?
Our estimate puts fair value at kr 1.69, about 30% lower versus a price of kr 2.43 (overvalued). Cautious scenario kr 1.27, optimistic scenario kr 2.12. The calculation is refreshed regularly with new filings.
What is the revenue of Enzymatica publ AB (ENZY)?
Enzymatica publ AB reported trailing-twelve-month revenue of about 51.5M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Enzymatica publ AB (ENZY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enzymatica publ AB it is kr 1.69 per share (as of Nov 10, 2026), against a price of kr 2.43.
Is Enzymatica publ AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ENZY trades above its calculated fair value: price kr 2.43, fair value kr 1.69, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENZY?
No. The price is what the market pays today (kr 2.43); the fair value is what the company's own numbers justify (kr 1.69). For Enzymatica publ AB the two are kr 0.7400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enzymatica publ AB worth?
The market values Enzymatica publ AB at about 590M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 2.43; our models calculate a fair value of kr 1.69 per share.
What do the bullish and bearish scenarios say about ENZY?
Our models span a range for Enzymatica publ AB: cautious scenario kr 1.27, base kr 1.69, optimistic kr 2.12 per share (as of Nov 10, 2026, price kr 2.43). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enzymatica publ AB (ENZY)?
Balance-sheet figures for Enzymatica publ AB (as of Nov 10, 2026): return on equity −36.1%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is ENZY from its 52-week high?
Enzymatica publ AB trades at kr 2.43, about 24% below its 52-week high of kr 3.20 and 48% above the low of kr 1.65 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.69 is for.
Which stocks are comparable to Enzymatica publ AB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enzymatica publ AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 2.43, calculated fair value kr 1.69 (−30%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Enzymatica publ AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enzymatica publ AB (ENZY)?
The closing price on Nov 10, 2026 was kr 2.43. Our estimate is kr 1.69, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enzymatica publ AB right now?
The price sits above even our optimistic bull case (kr 2.12). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Enzymatica publ AB

How large is the market capitalisation of Enzymatica publ AB (ENZY)?
The market capitalisation of Enzymatica publ AB is 590M SEK (≈ $59.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enzymatica publ AB (ENZY)?
The price-to-sales ratio of Enzymatica publ AB is 12.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enzymatica publ AB (ENZY)?
Earnings per share at Enzymatica publ AB are kr −0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Enzymatica publ AB (ENZY)?
The net margin of Enzymatica publ AB is −80.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Enzymatica publ AB (ENZY)?
The return on equity (ROE) of Enzymatica publ AB is −36.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enzymatica publ AB (ENZY)?
On an EBIT basis the return on assets of Enzymatica publ AB is −33.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Enzymatica publ AB (ENZY)?
The operating margin of Enzymatica publ AB is −26.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Enzymatica publ AB (ENZY)?
Revenue at Enzymatica publ AB is growing −2.9% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Enzymatica publ AB (ENZY) generate?
The free cash flow of Enzymatica publ AB is −41.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Enzymatica publ AB (ENZY) hold?
Enzymatica publ AB holds more cash than debt, 32.1M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Enzymatica publ AB in the live analysis

One click puts Enzymatica publ AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.